Back to Stocks

LIVN

LivaNova PLC
7 filings tracked
healthcaremedical devicesMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

LivaNova is demonstrating a powerful operational pivot, characterized by a 14.3% surge in quarterly revenue to $362.3 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, LivaNova's profitability remains under pressure. Operating income fell nearly 15% year-over-year to $41.5 million, as cost of sales rose faster than revenue, leading to a slip in gross margins.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every LIVN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

LivaNova's latest filing presents a company at a critical inflection point, balancing high-growth potential against lingering financial obligations. The operational data is undeniably positive, with double-digit revenue growth and a landmark FDA approval that opens a massive new market. The strategic shift toward a diversified medtech portfolio is evident, and the early repayment of debt suggests a management team focused on financial stability. However, the synthesis of the data reveals a precarious bridge to that future. The company is essentially racing to commercialize its new OSA platform before its cash reserves are depleted by legacy liabilities and acquisition earn-outs. While the resolution of the SNIA litigation guarantee is a major win, the remaining $389.5 million liability remains a heavy weight on the balance sheet. Investors must now weigh the high-conviction growth catalysts of the aura6000 launch against the reality of margin compression and substantial upcoming cash outflows.

Selected Quarter

Core Takeaway

LivaNova is transitioning from a litigation-burdened entity to a growth-oriented medtech player, but immediate liquidity risks from earn-outs and environmental liabilities persist.

Investor Lens

The trade-off is between the long-term valuation upside of a new multi-billion dollar market (OSA) and the short-term risk of a liquidity squeeze.

Watch Next

Commercial adoption rates of the aura6000 system and the final settlement/payment timing of the SNIA environmental liability.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.10Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%
bearishMay 6

Operating income declined 14.7% despite double-digit revenue growth.

earnings miss
60%
bullishMay 6

FDA PMA approval for aura6000 opens a new multi-billion dollar market.

guidance raise
80%
bearishMay 6

Gross margin slipped as cost of sales grew faster than revenue.

margin compression
50%
bullishMay 6

Early repayment of $95.9 million in term facilities reduces long-term debt.

debt restructure
70%

Filing History

10-QMay 6, 2026
Expand Sequence

LivaNova's latest filing presents a company at a critical inflection point, balancing high-growth potential against lingering financial obligations. The operational data is undeniably positive, with double-digit revenue growth and a landmark FDA approval that opens a massive new market. The strategic shift toward a diversified medtech portfolio is evident, and the early repayment of debt suggests a management team focused on financial stability. However, the synthesis of the data reveals a precarious bridge to that future. The company is essentially racing to commercialize its new OSA platform before its cash reserves are depleted by legacy liabilities and acquisition earn-outs. While the resolution of the SNIA litigation guarantee is a major win, the remaining $389.5 million liability remains a heavy weight on the balance sheet. Investors must now weigh the high-conviction growth catalysts of the aura6000 launch against the reality of margin compression and substantial upcoming cash outflows.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.